Key result
Trastuzumab deruxtecan maintains tumor response without LVEF decline or recurrent HF after previous cardiotoxicity.
Why the study?
Trastuzumab-induced cardiotoxicity can require discontinuation of adjuvant HER2-targeted therapy, and evidence on subsequent treatment strategies for disease recurrence in patients with prior trastuzumab-related heart failure remains limited.
Is trastuzumab deruxtecan feasible, effective, and safe from a cardiac standpoint in a patient with recurrent HER2-positive breast cancer and a history of recovered trastuzumab-induced heart failure?
Case Report (n=1)
No
Is trastuzumab deruxtecan feasible, effective, and safe from a cardiac standpoint in a patient with recurrent HER2-positive breast cancer and a history of recovered trastuzumab-induced heart failure?
This case report demonstrates that trastuzumab deruxtecan can be safely and effectively administered over 10 months without recurrent cardiotoxicity in a patient with metastatic breast cancer and prior trastuzumab-induced heart failure once LVEF has recovered.
Answers are grounded in this paper and cite their sources.
Supports cautious trastuzumab deruxtecan use after LVEF recovery in prior cardiotoxicity with monitoring; leaves open prospective safety confirmation.
Background : Trastuzumab-induced cardiotoxicity is a well-recognized complication that may lead to discontinuation of adjuvant HER2-targeted therapy. Evidence regarding subsequent treatment strategies for recurrence in patients with a history of trastuzumab-related heart failure remains limited. Case presentation : A woman with HER2-positive early breast cancer received adjuvant trastuzumab after surgery. Her baseline left ventricular ejection fraction (LVEF) was in the 60% range. During therapy, she developed acute heart failure with LVEF decline to 30%, requiring a one-week hospitalization and discontinuation of trastuzumab. Her cardiac function gradually recovered to the 60% range under standard heart failure management. Approximately 43 months later, she developed recurrence with liver metastases and multiple lymph nodes metastasis. Her cardiologist didn’t allow re-anti-HER2therapy, and we kept chemotherapy without anti-HER2 drugs. Two years later, given her recovered cardiac function and disease progression, trastuzumab deruxtecan (T‑DXd) was started. She received 13 cycles over 10 months, achieving durable tumor response without cardiac deterioration. Conclusion : This case illustrates that T‑DXd can be a feasible and effective option for recurrent HER2-positive breast cancer in patients with prior trastuzumab-induced heart failure, when cardiac function has sufficiently recovered and careful cardio-oncology monitoring is ensured.
No takes yet. Share an insight, caveat, or question.
Hiromi Fuchikami (2026) conducted a case report in Recurrent HER2-positive breast cancer with prior trastuzumab-induced heart failure (n=1). Trastuzumab deruxtecan (T-DXd) was evaluated on Tumor response and cardiac safety (LVEF stability and absence of heart failure symptoms). Trastuzumab deruxtecan achieved a 10-month tumor response over 13 cycles without LVEF decline or heart failure recurrence in a patient with recovered trastuzumab-induced cardiomyopathy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: